NO20016380L - Procedure for preventing tumor growth - Google Patents

Procedure for preventing tumor growth

Info

Publication number
NO20016380L
NO20016380L NO20016380A NO20016380A NO20016380L NO 20016380 L NO20016380 L NO 20016380L NO 20016380 A NO20016380 A NO 20016380A NO 20016380 A NO20016380 A NO 20016380A NO 20016380 L NO20016380 L NO 20016380L
Authority
NO
Norway
Prior art keywords
tumor growth
procedure
preventing tumor
preventing
ltbr
Prior art date
Application number
NO20016380A
Other languages
Norwegian (no)
Other versions
NO20016380D0 (en
Inventor
Daniela N Maennel
Thomas Hehlgans
Carola Seitz
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1999129488 external-priority patent/DE19929488A1/en
Priority claimed from DE2000104447 external-priority patent/DE10004447A1/en
Application filed by Basf Ag filed Critical Basf Ag
Publication of NO20016380L publication Critical patent/NO20016380L/en
Publication of NO20016380D0 publication Critical patent/NO20016380D0/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/525Tumour necrosis factor [TNF]
    • C07K14/5255Lymphotoxin [LT]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Fremgangsmåte for forhindring av betennelser, autoimmune sykdommer og tumorvekst ved å undertrykke LTBR-mediert aktivering, beskrives.Methods for preventing inflammation, autoimmune diseases and tumor growth by suppressing LTBR-mediated activation are described.

NO20016380A 1999-06-28 2001-12-27 Procedure for preventing tumor growth NO20016380D0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE1999129488 DE19929488A1 (en) 1999-06-28 1999-06-28 Treatment of inflammation, autoimmune disease and tumors by suppressing activation mediated by the lymphotoxin beta-receptor
DE2000104447 DE10004447A1 (en) 2000-02-03 2000-02-03 Treatment of inflammation, autoimmune disease and tumors by suppressing activation mediated by the lymphotoxin beta-receptor
PCT/EP2000/005738 WO2001000228A1 (en) 1999-06-28 2000-06-21 Method for preventing tumoral growth

Publications (2)

Publication Number Publication Date
NO20016380L true NO20016380L (en) 2001-12-27
NO20016380D0 NO20016380D0 (en) 2001-12-27

Family

ID=26004148

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20016380A NO20016380D0 (en) 1999-06-28 2001-12-27 Procedure for preventing tumor growth

Country Status (20)

Country Link
EP (1) EP1189626B1 (en)
JP (1) JP3822822B2 (en)
KR (1) KR20020016852A (en)
CN (1) CN1359297A (en)
AT (1) ATE410180T1 (en)
AU (1) AU5406000A (en)
BG (1) BG106246A (en)
BR (1) BR0012006A (en)
CA (1) CA2376920A1 (en)
DE (1) DE50015391D1 (en)
ES (1) ES2313893T3 (en)
HK (1) HK1047045A1 (en)
HU (1) HUP0201804A2 (en)
IL (1) IL147180A0 (en)
MX (1) MXPA01013367A (en)
NO (1) NO20016380D0 (en)
PL (1) PL353057A1 (en)
SK (1) SK18852001A3 (en)
TR (1) TR200103841T2 (en)
WO (1) WO2001000228A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL134994A0 (en) 2000-03-09 2001-05-20 Yeda Res & Dev Coupled two way clustering analysis of data
KR20050090420A (en) 2002-12-26 2005-09-13 다케다 야쿠힌 고교 가부시키가이샤 Metastin derivative and use thereof
WO2006001499A2 (en) 2004-06-25 2006-01-05 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
JP2009510172A (en) * 2005-10-04 2009-03-12 ジョンズ ホプキンス ユニバーシティ Compositions and methods for treating inflammation
US8404643B2 (en) 2005-12-22 2013-03-26 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
AR058584A1 (en) 2005-12-22 2008-02-13 Takeda Pharmaceutical METASTININE DERIVATIVES AND USE OF THE SAME
TWI404726B (en) 2006-10-25 2013-08-11 Takeda Pharmaceutical Metastin derivatives and use thereof
US8440185B2 (en) 2006-12-26 2013-05-14 The Johns Hopkins University Compositions and methods for the treatment of immunologic disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
AU726357B2 (en) * 1996-10-25 2000-11-02 Biogen Idec Ma Inc. Soluble lymphotoxin-beta receptors, anti-lymphotoxin receptor antibodies, and anti-lymphotoxin ligand antibodies as therapeutic agents for the treatment of immunological diseases
BR9908214A (en) * 1998-01-30 2000-11-28 Biogen Inc Treatment for follicular lymphomas using lymphotoxin pathway inhibitors (lt)

Also Published As

Publication number Publication date
HUP0201804A2 (en) 2002-09-28
BG106246A (en) 2002-10-31
SK18852001A3 (en) 2002-12-03
IL147180A0 (en) 2002-08-14
JP2003503359A (en) 2003-01-28
ES2313893T3 (en) 2009-03-16
CN1359297A (en) 2002-07-17
HK1047045A1 (en) 2003-02-07
MXPA01013367A (en) 2002-07-02
BR0012006A (en) 2002-03-12
PL353057A1 (en) 2003-10-06
TR200103841T2 (en) 2002-06-21
DE50015391D1 (en) 2008-11-20
CA2376920A1 (en) 2001-01-04
ATE410180T1 (en) 2008-10-15
AU5406000A (en) 2001-01-31
JP3822822B2 (en) 2006-09-20
EP1189626A1 (en) 2002-03-27
KR20020016852A (en) 2002-03-06
EP1189626B1 (en) 2008-10-08
NO20016380D0 (en) 2001-12-27
WO2001000228A1 (en) 2001-01-04

Similar Documents

Publication Publication Date Title
CA2388646A1 (en) Methods and compositions utilizing quinazolinones
WO2004009776A3 (en) TREATMENT OF TNFα RELATED DISORDERS
NO20045043L (en) Pyrimidinone Compounds, Compositions and Methods
GB2368796A (en) Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
ATE415979T1 (en) TREATMENT WITH ANTI-ERBB2 ANTIBODIES
TR199802676A3 (en) Method for the treatment and prevention of tumors, tumor-related diseases and cachexia.
AU3998400A (en) Methods of treating c1s-mediated diseases and conditions, and compounds and compositions therefor
WO2003088903A3 (en) Compounds, compositions, and methods
WO2003057163A3 (en) Methods for preparing immunoconjugates
AU2079901A (en) Thrombopoietin mimetics
EA200001129A3 (en) METHOD OF OBTAINING 4-CARBOXYAMINO-2-SUBSTITUTE-1,2,3,4-TETRAHYDROCHINOLINE
AU2003297318A1 (en) Methods and compositions for treating cancer using 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 21617, 39228, 49928, 54476.
WO2001017543A3 (en) Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
HK1040983A1 (en) Quinones for treatment of diseases.
AU2003252025A1 (en) Compounds, compositions, and methods
NO20016380L (en) Procedure for preventing tumor growth
AU7847800A (en) Topical anesthetics useful for treating cancer, autoimmune diseases and ischemia
WO2001041709A3 (en) Methods for treating cell death diseases and inflammation
MXPA02005069A (en) Tr3 specific binding agents and methods for their use.
AU2001230243A1 (en) Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic diseases or stroke
ZA200203166B (en) Treatment of cancer.
AU2607999A (en) Sustained release implant, methods for preparation thereof and for treating cancer
AU2202301A (en) Cd45 inhibitors
AU6234000A (en) Methods for treating autoimmune diseases
AU3503200A (en) Compounds, compositions, and methods for photodynamic therapy

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application